Purpose of this Study
We are doing this study to find out if an experimental drug called ABBV-303 (the study drug) is a safe and effective option for various solid tumor forms of cancer.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with solid tumor cancer (including non-small cell lung cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma, colorectal cancer, or renal cell cancer) that has spread
- Have received standard therapy options for their type of cancer
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will:
- Take the study drug alone or in combination with a drug called budigalimab
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-303, as monotherapy and in combination with budigalimab (ABBV-181), in adult subjects with advanced solid tumors
Principal Investigator
Jeffrey
Clarke
Protocol Number
PRO00114729
NCT ID
NCT06158958
Phase
I
Enrollment Status
Pending Open to Enrollment